SOLIRIS (eculizumab): The first treatment specifically approved for PNH

SOLIRIS Resources

Other resources for information about PNH and SOLIRIS

Other resources for information about PNH and SOLIRISThe more you know, the better you will be able to manage PNH. Here are other sources of information that may be useful

Doctor discussion guide
Questions you may want to ask, and other tips and tools that can help you get the most from your doctor visit.

Links to related sites
Places to find good information and make connections with other PNH patients on the web.

Printable SOLIRIS® (eculizumab) materials
PDFs of PNH and SOLIRIS patient materials.

SOLIRIS Registration
Learn and share. Register to be part of the SOLIRIS community. Get news, updates, emails, newsletters and more.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.